Achieve Life Sciences has announced the completion of a final follow-up visit for the last patient in its OCRA-3 trial investigating cytisinicline for smoking cessation and nicotine dependence. The final milestone within the Phase III trial will now allow determination of the primary endpoint – measured by continuous abstinence during the last four weeks of treatment.
According to the World Health Organisation, tobacco use is currently the leading cause of preventable death worldwide – responsible for more than eight million mortalities per year. Currently, nicotine-based treatment dominates smoking cessation markets. If approved by FDA, cytisinicline, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, would be the first non-nicotine smoking prescription treatment in the US in nearly 20 years.
Go deeper with GlobalData
“The trial will be determined to be successful if either or both of the cytisinicline treatment arms show a statistical benefit when compared independently to the placebo arm,” the company said.
The blinded, placebo-controlled trial operated across 20 clinical locations, with 792 subjects received 3mg cytisinicline, dosed 3 times daily for either 6 or 12 weeks, and monitored through 24 weeks post-randomisation. Topline data is expected in the second quarter of 2023.
Earlier in 2023, the company announced the last follow-up visit for the ORCA-V1 trial. The ORCA-V1 is investigating cytisinicline for cessation of nicotine e-cigarette users.
See Also:
“We are pleased to have reached this final milestone in the Phase 3 ORCA-3 trial and continue to expect topline data results from this trial, as well as results from the ORCA-V1 trial of cytisinicline as a treatment for e-cigarette cessation, to be reported in the second quarter of this year,” commented John Bencich, CEO of Achieve.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company, headquartered in Washington, US, announced total net loss of $42.4m in 2022.
